Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF
The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more tha...
Hospital Intervention Fails to Improve Heart Failure Outcomes
A clinical trial of an intervention designed to im...
Even 10 Minutes of Exercise Beneficial After ICD Implantation
Small increases in daily physical activity are ass...
Iron-Clad Benefits of CRT Seen in Reduced-EF Heart Failure
The case for the use of intravenous iron therapy f...
Dispatch System Boosts Bystander CPR in Those With Limited English
The improved Los Angeles medical dispatch system p...
Covid ‘doesn’t discriminate by age’: Serious cases on the rise in younger adults
After spending much of the past year tending to el...
Dapagliflozin Effective in Both Women and Men With Heart Failure With Reduced Ejection Fraction
NEW YORK (Reuters Health) – Unlike some hear...
Global Registry Refines COVID-19 Risk in Adult Congenital HD
Find the latest COVID-19 news and guidance in Meds...
FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF
The US Food and Drug Administration (FDA) has appr...
